Newsmeme!
Discover News you didn't know existed
NEW YORK----Reportlinker.com announces that a new market research report related to the Chemicals industry industry is available in its catalogue.
NEW YORK----Reportlinker.com announces that a new market research report related to the Medical devices industry is available in its catalogue.
Morphotek, a subsidiary of Eisai Corporation of North America, has started a multi-centered Phase II study of farletuzumab. The study will evaluate farletuzumab, plus the chemotherapy drug paclitaxel, in patients with platinum-resistant ovarian cancer.
BALTIMORE — Saturday at noon, the Fort Hill Sentinels will play the Dunbar Poets for the Maryland Class 1A state football championship. The following directions to M&T Bank Stadium in Baltimore can be found on the Maryland Public Secondary Schools Athletic Association web site, www.mpssaa.org:
"It was my obstetrician gynecologist (OB/GYN) that found the lump in my breast and sent me for a diagnostic mammogram and ultrasound. A few weeks later, I received a letter from the imaging center that did the mammogram and they said it was normal and to come back in a year.
Questions and answers on Daily Bulletin stories from readers like you. The Folga golf group, established by Joe Toledo of Chino to share friendships and to raise funds for City of Hope cancer research, will hold its club championship Sunday at Los Serranos South.
ANDERSON — A prominent, retired Anderson surgeon was identified Tuesday as the driver who died in a crash while taking himself to an emergency room a day earlier.Dr. William J. Tierney, 74, was pronounced dead at Community Hospital shortly after his car was involved in a single-vehicle accident on Vanbuskirk Road in Anderson at 5:44 p.m. Monday.
Two studies, presented this week at the 94th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), concluded a novel technique can improve outcomes for patients with vertebral compression fractures (VCF) caused by malignant tumors in the spine.
Morphotek ® , Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of farletuzumab (also known as MORAb-003). The study will evaluate farletuzumab, plus the chemotherapy drug paclitaxel, in patients with platinum-resistant (PR) ovarian cancer. The randomized, controlled trial will compare farletuzumab plus paclitaxel with ...
EXTON, Pa.----Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of farletuzumab . The study will evaluate farletuzumab, plus the chemotherapy drug paclitaxel, in patients with platinum-resistant ovarian cancer.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |